https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...

Faced with the prospect of tariffs on imported medicines threatened by the Trump administration, Indian drugmaker Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations ...

Multiple domestic pharmaceutical companies launched generic semaglutide on Saturday, a day after the drug's patent expired in India, with prices falling by as much as 90% from the branded version, ...

MUMBAI – A deluge of weight-loss drugs is set to transform the global fight against obesity, as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent ...

The Democratic Party continues to lead over Republicans in the battle to control the House of Representatives, but by a slimmer margin than two months ago. The latest Rasmussen Reports national ...

NEW DELHI: With prices of GLP-1 drugs crashing and their generic versions flooding the market, govt has cracked down on their misuse, inspecting 49 businesses and issuing notices while also flagging ...

Pharmaceutical stocks are expected to remain in focus as competition in the domestic market picks up pace following the patent expiry of Semaglutide, a widely prescribed drug for diabetes and weight ...

HYDERABAD: India’s pharmaceutical exports touched nearly USD 28.29 billion by February this financial year, marking a 5.6% growth compared to last year, a top official said at the Chintan ...

MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the innovator ...

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close. In January 2025, Axsome added a third product to its lineup with the U.S. Food and ...